Rezolute Inc NASDAQ:RZLT Rezolute is advancing targeted therapies for rare, metabolic, and life-threatening diseases. Its lead clinical asset, RZ358, is in Phase 2b development as a potential treatment for CHI, a rare pediatric endocrine disorder. Its pipeline also includes RZ402, an IND-ready orally available plasma kallikrein inhibitor, which is staged to transition into clinical development for the treatment of diabetic macular edema.

Location: 201 Redwood Shores Pkwy Ste 315, California, 94065-1134, United States | Website: www.rezolutebio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing